Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Neoplasms 67Lymphoma 56Multiple Myeloma 53Breast Neoplasms 52Neoplasm Metastasis 47Lung Neoplasms 47Prostatic Neoplasms 46Leukemia, Myeloid, Acute 40Ovarian Neoplasms 39Melanoma 37Carcinoma, Non-Small-Cell Lung 37Hematologic Neoplasms 36Colorectal Neoplasms 32Pancreatic Neoplasms 29Glioma 28Lymphoma, Non-Hodgkin 26Urinary Bladder Neoplasms 25Sarcoma 25Carcinoma, Renal Cell 25Brain Neoplasms 23Neuroblastoma 21Myelodysplastic Syndromes 21Triple Negative Breast Neoplasms 19Fallopian Tube Neoplasms 19Stomach Neoplasms 18Leukemia, Lymphocytic, Chronic, B-Cell 18Burkitt Lymphoma 18Small Cell Lung Carcinoma 17Colonic Neoplasms 17Glioblastoma 16

Interventions

Metformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hyperplasia × 90 days × Clear all
NCT02581137 2026-04-13

Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion

National Cancer Institute (NCI)

Phase 2 Active not recruiting
26 enrolled 10 charts
Head & Neck

Erythroplasia, Hyperplasia, Leukoplakia, Oral, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡